Neurogene Inc. SEC filings NGNE
Neurogene Inc. has 750 filings in SEC EDGAR's recent list, going back to Jun 25, 2007. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 16, 2026 | — |
| DEF 14A | Proxy statement | Apr 16, 2026 | Jun 3, 2026 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Apr 25, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Apr 26, 2024 |
| DEFA14A | Additional proxy material | Apr 27, 2023 | — |
| DEF 14A | Proxy statement | Apr 27, 2023 | Jun 8, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2023 | Jun 8, 2023 |
| DEFA14A | Additional proxy material | Mar 31, 2022 | — |
| DEF 14A | Proxy statement | Mar 31, 2022 | May 12, 2022 |
| DEFA14A | Additional proxy material | Mar 31, 2021 | — |
| DEF 14A | Proxy statement | Mar 31, 2021 | May 13, 2021 |
| DEFA14A | Additional proxy material | Apr 16, 2020 | — |
| DEFA14A | Additional proxy material | Mar 24, 2020 | — |
| DEF 14A | Proxy statement | Mar 24, 2020 | May 5, 2020 |
| DEFA14A | Additional proxy material | Oct 2, 2019 | — |
| DEF 14A | Proxy statement | Oct 2, 2019 | Nov 12, 2019 |
| PRE 14A | Preliminary proxy statement | Sep 20, 2019 | Nov 12, 2019 |
| DEFA14A | Additional proxy material | Mar 26, 2018 | — |
| DEF 14A | Proxy statement | Mar 26, 2018 | May 7, 2018 |
| DEFA14A | Additional proxy material | Mar 28, 2017 | — |
| DEF 14A | Proxy statement | Mar 28, 2017 | May 8, 2017 |
| DEFA14A | Additional proxy material | Mar 25, 2016 | — |
| DEF 14A | Proxy statement | Mar 25, 2016 | May 9, 2016 |
| DEFA14A | Additional proxy material | Mar 27, 2015 | — |
| DEF 14A | Proxy statement | Mar 27, 2015 | May 11, 2015 |
Showing 27 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NGNE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1404644
- Former names
- Neoleukin Therapeutics, Inc. (until Dec 6, 2023); AQUINOX PHARMACEUTICALS, INC (until Aug 12, 2019); AQUINOX PHARMACEUTICALS (USA) INC (until Dec 24, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.